Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes

NCT07096297 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT07096297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07096297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2025
Completion date
August 31, 2030
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

mds (myelodysplastic syndrome)